Table 3 Incidence, severity, treatment and outcomes of patients who had irAEs
irAEs | Grade (n = 414) | Median onset,days (range) | Median Time to Resolution, days (range) | irAE specific Treatment (n, %) | Termination of ICI due to irAE (n, %) | irAE Recovery (n, %) | ICI rechallenge (n, %) | Recurrence of irAE after rechallenge (n, %) | ||
|---|---|---|---|---|---|---|---|---|---|---|
All | Gr 1–2 | Gr 3–5 | ||||||||
Overall | 98 (23.7) | 75 (18.1) | 23 (5.6) | 63 (1–526) | 51 (1–951) | 56/98 (57.1) | 22/98 (22.5) | 84/98 (85.7) | 68/98 (69.4) | 11/68 (11.2) |
Endocrine | ||||||||||
 Hypothyroid | 31 (7.5) | 31 (7.5) | – | 112 (19–574) | 168 (11–804) | 25/31 (80.7) | 5/31 (16.1) | 25/31 (80.7) | 21/31 (67.7) | 1/21 (4.8) |
 Hyperthyroid | 11 (2.7) | 11 (2.7) | – | 47 (15–203) | 35 (12–751) | 6/11 (54.6) | 0 | 10/11 (90.9) | 8/11 (72.7) | 0/8 |
 Hypophysitis | 5 (1.2) | 4 (1.0) | 1 (0.2) | 178 (1–348) | 208 (54–807) | 5/5 (100) | 1/5 (20.0) | 5/5 (100) | 4/5 (80.0) | 0/4 |
GI | ||||||||||
 Colitis | 1 (< 0.01) | – | 1 (< 0.01) | 475 | 181 | 1 | 0 | 1 | 1 | 0 |
 Hepatitis | 27 (6.5) | 22 (5.3) | 5 (1.2) | 42 (7–400) | 42 (7–632) | 5/27 (18.5) | 8/27 (29.6) | 23/27 (85.2) | 17/27 (63.0) | 3/17 (17.7) |
 Pancreatitis | 11 (2.7) | 9 (2.2) | 2 (0.5) | 30 (14–254) | 84 (1–707) | 1/11 (9.1) | 1/11 (9.1) | 9/11 (81.8) | 10/11 (90.9) | 4/10 (40.0) |
Lung | ||||||||||
 Pneumonitis | 6 (1.4) | 3 (0.7) | 3 (0.7) | 34 (23–139) | 18.5 (8–33) | 5/6 (83.3) | 2/6 (33.3) | 6/6 (100) | 3/6 (50.0) | 0/3 |
Skin | ||||||||||
 Rash | 20 (4.8) | 17 (4.1) | 3 (0.7) | 55.5 (3–420) | 34 (7–253) | 14/20 (70.0) | 4/20 (20.0) | 18/20 (90.0) | 17/20 (85.0) | 4/17 (23.5) |
 Vitiligo | 1 (< 0.01) | 1 (< 0.01) | – | 70 | 951 | 1 | 0 | 0 | 1 | 1 |
Others | ||||||||||
 Others | 8 (2.0) | 4 (1.0) | 4 (1.0) | 181.5 (2–505) | 31.5 (20–86) | 4/8 (50.0) | 2/8 (25.0) | 7/8 (87.5) | 4/8 (50.0) | 0/4 |